In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease

  • Hanseul Park
  • , Jungju Oh
  • , Gayong Shim
  • , Byounggook Cho
  • , Yujung Chang
  • , Siyoung Kim
  • , Soonbong Baek
  • , Hongwon Kim
  • , Jeain Shin
  • , Hwan Choi
  • , Junsang Yoo
  • , Junyeop Kim
  • , Won Jun
  • , Minhyung Lee
  • , Christopher J. Lengner
  • , Yu Kyoung Oh
  • , Jongpil Kim

Research output: Contribution to journalArticlepeer-review

244 Scopus citations

Abstract

In vivo gene editing in post-mitotic neurons of the adult brain may be a useful strategy for treating neurological diseases. Here, we develop CRISPR–Cas9 nanocomplexes and show they were effective in the adult mouse brain, with minimal off-target effects. Using this system to target Bace1 suppressed amyloid beta (Aβ)-associated pathologies and cognitive deficits in two mouse models of Alzheimer’s disease. These results broaden the potential application of CRISPR–Cas9 systems to neurodegenerative diseases.

Original languageEnglish
Pages (from-to)524-528
Number of pages5
JournalNature Neuroscience
Volume22
Issue number4
DOIs
StatePublished - 1 Apr 2019

Fingerprint

Dive into the research topics of 'In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this